Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: A systematic review and meta-analysis.
Mohitosh BiswasShawonur RahamanTapash Kumar BiswasBaharudin IbrahimPublished in: Expert opinion on drug safety (2020)
The ABCB1 C3435T homozygous mutant (TT) was associated with significantly increased risk of MACE compared to either wild type genotype (CC) or the combination of wild type and heterozygous genotypes (TT vs. CC: RR 1.33; 95% CI 1.06-1.68; p=0.02; TT vs. CC+CT: RR 1.32; 95% CI 1.10-1.60; p=0.004). Safety outcomes, i.e. bleeding events were not significantly different between the genetic models investigated (TT vs. CC: RR 1.93; 95% CI 0.86-4.35; p=0.11; TT vs. CC+CT: RR 1.36; 95% CI 0.89-2.09; p=0.16; CT+TT vs. CC: RR 1.20; 95% CI 0.59-2.44; p=0.61). It is suggested that ABCB1 C3435T genotype should be tested for ACS/CAD patients undergoing PCI to ensure optimum therapy of clopidogrel.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- coronary artery disease
- wild type
- cardiovascular events
- antiplatelet therapy
- st segment elevation myocardial infarction
- patients undergoing
- acute myocardial infarction
- coronary artery bypass grafting
- st elevation myocardial infarction
- image quality
- dual energy
- computed tomography
- contrast enhanced
- type diabetes
- magnetic resonance imaging
- atrial fibrillation
- early onset
- coronary artery bypass
- dna methylation
- mass spectrometry
- skeletal muscle
- atomic force microscopy
- genome wide
- single molecule
- transcatheter aortic valve replacement
- newly diagnosed
- replacement therapy
- metabolic syndrome
- gene expression